The effect of long-term pharmacological antilipolysis on substrate metabolism in growth hormone (GH)-substituted GH-deficient adults.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

The lipolytic properties of GH are essential for the acute effects on glucose metabolism and insulin sensitivity, whereas its more long-term impact on substrate metabolism is uncertain.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.

Each person switched between Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison at some point, usually with a gap in between.

At the end of each period glucose and lipid oxidation rates were assessed by indirect calorimetry, and the protein oxidation rate was estimated by urinary excretion of urea.

Endogenous glucose production and whole body protein metabolism were assessed by isotope dilution techniques using tritiated glucose and stable phenylalanine and tyrosine isotopes, respectively.

What Was Measured

Topics PubMed links to this paper include Body Composition, Growth Hormone, Hormones, Human Growth Hormone, Hypolipidemic Agents, Lipoprotein Lipase and Lipoproteins.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The publication is from 2002 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.